top of page
Sky Health Wellness Clinic Las Vegas Insulin Diabetes Treatment 2025 1c.jpg

Sky Health Wellness Clinic:
All About Insulin 

All About Insulin Page Index 

What is Insulin?

​

The History of Insulin

​

How is Insulin Produced​

​​

Chemical Composition & Structure of Insulin

​

Known Medical Applications of Insulin

​

Methods of Insulin Administration​

​

Possible Side Effects of Insulin​

​

Benefits of Insulin Use

​

Innovations in Insulin Delivery & Development​

​

Insulin Global Statistics & Insulin Usage Trends

​

The Future of Insulin & Diabetes Management

​

Resources Used for All About Insulin

​

This page and all it's information is meant to strictly be informative and help provide insight to the topic of insulin. Sky Health Wellness Clinic is not advertising or recommending any treatments or brands

represented here. Any outside links are to help inform readers and do not serve as an endorsement of any kind. While this page provides information regarding insulin it is still best practice to always consult your primary care provider about any health issues. If you have questions or find any information that needs correction or updates please use our contact form to inform us. Our team will always strive to provide the most accurate and up to date information, so we can best assist you.​

What is Insulin?

Insulin is a hormone essential to the metabolism of carbohydrates, fats, and proteins, is one of the most important biochemical substances in the human body. Secreted by the pancreas, insulin regulates the uptake of glucose from the bloodstream into tissues, ensuring that cells receive the energy they need to function properly. Its role is so vital that a failure to produce or use insulin effectively leads to diabetes mellitus, a chronic condition affecting over half a billion people worldwide.

​

Diabetes exists in several forms, with type 1 diabetes being characterized by a complete lack of insulin production and type 2 diabetes involving a gradual decline in insulin sensitivity or secretion. In both cases, insulin plays a therapeutic role, and the availability of exogenous insulin has been nothing short of revolutionary in modern medicine. Before its discovery in the 1920s, a diagnosis of type 1 diabetes was essentially a death sentence. Today, thanks to advancements in biotechnology, insulin therapy is not only accessible but highly customizable, offering millions of people the opportunity to live healthy, active lives.

​

Insulin is much more than just a treatment for diabetes. It has become a case study in how scientific discovery, medical necessity, and industrial innovation can intersect. From its origins in dog pancreases to modern production in genetically modified E. coli, insulin’s journey mirrors the growth of biomedical science over the past century.

​

On this page we will explore insulin’s entire life cycle; from its discovery and molecular composition to its clinical uses, delivery methods, and emerging frontiers in medicine. We will also examine the challenges facing patients today, such as the rising cost of insulin and limited access in lower-income countries. Finally, we'll assess the future of insulin and what it might look like in a world increasingly driven by technology, data, and personalized medicine.

​

Each section has been crafted to be both scientifically rigorous and accessible to a general audience, with the goal of demystifying insulin and emphasizing its importance not only as a drug but as a symbol of progress in medical science. As always we recommend you discuss any medication with your primary care provider to see if it's best for you. Your primary care provider should be able to answer any questions you may have on how any kind of medication will affect your body; as each individual has their own unique health needs.

The History of Insulin

The story of insulin is one of the most remarkable narratives in medical history. It is a tale of scientific curiosity, collaboration, experimentation, and ultimately, salvation for millions of people with diabetes.

 

Early Understanding of Diabetes

Diabetes mellitus has been known for millennia. Ancient Egyptian and Indian medical texts described symptoms that resemble those of diabetes; primarily excessive urination and unquenchable thirst. The term “diabetes” was first used by the Greek physician Aretaeus of Cappadocia in the 2nd century CE, derived from a word meaning “to siphon,” due to the excessive fluid loss observed in patients. Later, Thomas Willis in the 17th century added the term “mellitus” (Latin for honey-sweet), noting the sugary taste of urine in affected individuals; a common diagnostic method at the time.

Despite these early recognitions, the underlying cause of diabetes remained a mystery for centuries.

 

The Pancreas and Diabetes Connection

By the 19th century, anatomists had begun to uncover the structure and function of the pancreas. In 1869, German medical student Paul Langerhans identified clusters of cells in the pancreas that looked different from the surrounding exocrine tissue. These clusters were later named the “Islets of Langerhans.”

​

It wasn’t until the late 19th century that a connection between the pancreas and diabetes was proven. In 1889, German physiologist Oskar Minkowski and physician Joseph von Mering performed a series of experiments on dogs. When they removed the pancreas from a dog, it developed severe symptoms consistent with diabetes and died soon after. This landmark experiment firmly established the pancreas’s role in carbohydrate metabolism.

​

Still, the precise substance produced by the pancreas that controlled glucose metabolism remained unknown.

​

The Discovery of Insulin

The breakthrough came in the early 20th century in Toronto, Canada. Frederick Banting, a young surgeon with limited research experience, had the idea to isolate the internal secretion of the pancreas by ligating the pancreatic ducts of dogs, allowing the exocrine part to degenerate and leaving only the islets. He believed this would make it easier to extract the active anti-diabetic substance.

​

Banting presented his idea to John Macleod, a respected professor of physiology at the University of Toronto. Despite his initial skepticism, Macleod gave Banting lab space, equipment, and the help of Charles Best, a medical student. Their experiments began in May 1921.

​

By July of that year, Banting and Best were able to extract a substance from the pancreas that, when injected into diabetic dogs, significantly lowered their blood glucose levels. The active compound was named "insulin," from the Latin "insula," meaning island, referencing the islets of Langerhans.

​

In January 1922, the first human was treated with insulin. Leonard Thompson, a 14-year-old boy with severe type 1 diabetes, received an injection of partially purified insulin. The first dose caused an allergic reaction, but a refined extract prepared by biochemist James Collip proved successful. Thompson’s condition dramatically improved, and insulin was hailed as a miracle.

​

The Nobel Prize and Commercial Production

In 1923, the Nobel Prize in Physiology or Medicine was awarded to Frederick Banting and John Macleod for the discovery of insulin. Banting, unhappy that Charles Best was not included, shared his prize money with him. Macleod, in turn, shared his with Collip.

​

The discovery of insulin sparked a race to produce it on a large scale. Pharmaceutical companies, particularly Eli Lilly and Company in the United States, quickly partnered with the University of Toronto to manufacture insulin from the pancreases of cows and pigs. This animal-derived insulin was effective but not identical to human insulin, and allergic reactions were not uncommon.

 

Advances in Purification and Formulation

In the following decades, efforts were made to improve insulin purity and control its duration of action. Protamine zinc insulin, introduced in the 1930s, provided longer-lasting effects. Later formulations such as Neutral Protamine Hagedorn (NPH) and Lente insulin allowed better glycemic control through less frequent dosing.

​

Despite these advances, insulin therapy remained a burden due to the need for multiple daily injections and careful monitoring. It was also imprecise, early blood glucose tests were crude, and hypoglycemia was a frequent danger.

​

The Genetic Engineering Revolution

A pivotal change occurred in the 1970s with the advent of recombinant DNA technology. Scientists at Genentech succeeded in synthesizing the human insulin gene and inserting it into Escherichia coli (E. coli) bacteria. The bacteria, in turn, produced insulin identical to that made by the human pancreas.

​

This form of biosynthetic human insulin was approved by the U.S. Food and Drug Administration (FDA) in 1982 and marketed as Humulin. It was the first genetically engineered drug approved for human use and marked the dawn of the biotechnology era in medicine.

​

Recombinant insulin resolved many issues related to allergies and batch inconsistency that had plagued animal-derived insulin. It also opened the door for the development of insulin analogs; modified versions of insulin with tailored onset and duration of action.

​

Modern Insulin Analogs

The 1990s and 2000s saw the rise of insulin analogs, which mimic the body’s natural insulin secretion more closely. These include:

  • Rapid-acting insulins (e.g., lispro, aspart, glulisine): Begin working in 10–30 minutes and peak quickly.

  • Long-acting insulins (e.g., glargine, detemir, degludec): Provide a steady, 24-hour effect with no pronounced peak.

  • Ultra-rapid and ultra-long acting variants: Tailored for specific lifestyle needs or basal insulin replacement.

​

The analog era has dramatically improved glycemic control and reduced the risk of hypoglycemia, particularly in people with type 1 diabetes.

​

From Syringes to Smart Systems

Insulin delivery has evolved in parallel with its production. The shift from glass syringes to disposable plastic syringes, and later to insulin pens and pumps, has greatly improved convenience and precision. Continuous glucose monitors (CGMs) and insulin pumps now form closed-loop systems. These are often called artificial pancreases, that automate insulin delivery in real time.

​

These innovations allow people with diabetes to maintain near-normal blood glucose levels with minimal manual intervention.

How is Insulin Produced?

Modern insulin production is a high-precision, bioengineering feat that transforms microorganisms into tiny factories capable of generating one of the world’s most life-saving hormones. The shift from crude animal extraction to genetically engineered human insulin revolutionized diabetes treatment and laid the foundation for the biotech industry as we know it today.

​

This section explores the step-by-step process of how insulin is produced today going from genetic manipulation and fermentation to purification, formulation, and final product packaging.

​

From Pancreas to Petri Dish: A Brief History of Production
Before the advent of biotechnology, insulin was extracted from the pancreases of pigs and cows. This method was labor-intensive and imprecise, requiring nearly 2 tons of pig pancreas to produce just 8 ounces of insulin. While effective, animal insulin sometimes caused immune responses in humans due to slight structural differences.

​

The 1970s and 1980s ushered in the era of recombinant DNA technology. Scientists succeeded in creating biosynthetic human insulin by inserting the human insulin gene into a bacterial plasmid, effectively programming the microorganism to produce insulin. This form of insulin is molecularly identical to the insulin produced in the human body, greatly reducing allergic reactions and ensuring uniformity.

​

Step 1: Gene Isolation and Vector Construction
The production of biosynthetic insulin begins with genetic engineering. Scientists first isolate the gene that codes for human insulin. Human insulin is composed of two separate chains (A and B) that must fold and bind together to become biologically active.

​

Using bioinformatics tools, researchers identify the DNA sequences for both the A and B chains of insulin and synthetically create these sequences in a laboratory. These sequences are then inserted into plasmids, small, circular pieces of DNA used to deliver genetic material into host cells.

 

The host organisms of choice are usually:

Escherichia coli (E. coli) – a bacterium with fast reproduction rates and well-characterized genetics.

Saccharomyces cerevisiae – a type of yeast preferred for eukaryotic protein expression.

 

Step 2: Transformation and Host Cell Cultivation
The recombinant plasmids are introduced into the host microorganisms through a process known as transformation. Once inside the microbial cells, the insulin genes are incorporated into the host’s genome or remain on the plasmid, instructing the cell to produce the insulin precursor protein.

The transformed cells are cultured in large bioreactors, which are stainless steel vats that can hold thousands of liters of growth medium. These vessels are maintained under optimal conditions:

 

Temperature: Usually between 30°C and 37°C depending on the host organism.

pH: Carefully regulated to maintain enzyme function.

Oxygen: Pumped into the bioreactor to support aerobic metabolism.

Nutrients: Glucose, amino acids, and salts are added to support cell growth and protein production.

As the cells multiply, they begin producing the insulin precursor at large scale.

​

Step 3: Protein Harvesting
After several hours or days of fermentation, the microbial biomass reaches the desired density, and production is halted. The cells are then separated from the culture medium through centrifugation or filtration.

​

If the insulin is expressed inside the cells (which is often the case with E. coli), the next step is cell lysis—breaking open the microbial cells to release their contents. This can be done using:

​

Mechanical methods (e.g., high-pressure homogenization)

Chemical lysis agents (e.g., detergents)

Enzymatic digestion

​

The resulting slurry contains a mix of proteins, DNA, cell fragments, and the insulin precursor.

 

Step 4: Protein Purification
This is one of the most critical and complex steps. The insulin precursor must be separated from the thousands of other proteins and biomolecules present in the lysate. This involves several purification steps:

​

Precipitation - Removes unwanted proteins by altering pH or using ammonium sulfate.

Chromatography -Techniques such as ion exchange, affinity chromatography, and size exclusion help isolate insulin from contaminants.

Refolding - Since proteins can misfold after expression and lysis, they must be denatured and then allowed to refold under controlled conditions so they regain their functional 3D shape.

​

In recombinant insulin production, the A and B chains are often expressed separately. These chains are later chemically combined in vitro under oxidizing conditions to form the correct disulfide bonds.

At this stage, the product is called human insulin or biosynthetic insulin.

​

Step 5: Formulation and Stabilization
After purification, the insulin must be stabilized and prepared for medical use. This involves adjusting the pH, adding preservatives (e.g., phenol or m-cresol), and sometimes complexing insulin with other molecules (like zinc) to control its absorption profile.

​

Depending on the intended use, insulin is then formulated into various types:

​

Rapid-acting insulin – modified to absorb quickly after injection.

Intermediate-acting insulin – such as NPH, containing protamine to delay absorption.

Long-acting insulin analogs – such as glargine or degludec, which provide basal insulin levels for 24 hours or more.

​

Formulated insulin is filled into sterile vials, cartridges, or pre-filled pens under aseptic conditions to ensure safety and shelf stability.

​

Step 6: Quality Control and Testing
Insulin is a high-risk pharmaceutical, meaning it is subject to rigorous quality testing. Each batch must undergo:

​

Potency testing – to verify the concentration of active insulin.

Purity analysis – to ensure no contaminants or bacterial endotoxins are present.

Stability testing – to confirm the insulin maintains its activity over time under various storage conditions.

Sterility testing – to prevent infections from contaminated product.

​

Only after passing all tests can the insulin be released to market.

​

Environmental and Ethical Considerations
Because insulin production uses genetically modified organisms (GMOs), facilities must follow strict environmental controls to prevent accidental release. The use of GMOs in medicine is widely accepted, though it continues to raise regulatory and ethical questions, particularly regarding patenting biological sequences.

​

Furthermore, production of insulin must balance efficiency with global access. While the top manufacturers (Eli Lilly, Novo Nordisk, Sanofi) produce high-quality insulin, the market is dominated by just a few players. This affects pricing, supply stability, and access in developing countries.

 

Emerging Trends in Insulin Manufacturing
Biotech firms are continuously exploring ways to make insulin production faster, cheaper, and more adaptable:

Plant-based insulin - Some researchers are using genetically modified plants like safflower to produce insulin in their seeds.

Cell-free synthesis - A novel technique using only enzymes and genetic templates to produce proteins without living cells.

Continuous manufacturing - Replacing batch processing with ongoing production lines that reduce time and cost.

 

In addition, biosimilar insulin; essentially generic versions of branded insulin—is expanding access in many parts of the world. These products must demonstrate bioequivalence and undergo stringent regulatory review but offer a promising path toward lowering insulin prices.

Chemical Composition & Structure of Insulin

Insulin, though relatively small compared to many proteins, is intricately structured and highly specific in its function. Its unique chemical composition allows it to perform a critical role in cellular metabolism by binding precisely to insulin receptors and initiating a cascade of intracellular processes.

Understanding insulin’s molecular structure not only explains how it works but also guides how synthetic analogs are designed and how pharmaceutical formulations are optimized for therapeutic use.

 

Basic Molecular Characteristics

Human insulin is a polypeptide hormone, composed of 51 amino acids arranged in two distinct chains known as the A chain and the B chain. These chains are connected by disulfide bridges that stabilize the three-dimensional structure of the molecule.

​

  • A chain: 21 amino acids

  • B chain: 30 amino acids

  • Disulfide bonds: Two interchain (between A and B) and one intrachain (within A)

  • Molecular formula: C₂₅₇H₃₈₃N₆₅O₇₇S₆

  • Molecular weight: Approximately 5808 Daltons (Da)

​

The spatial arrangement of these chains and their chemical properties are essential for insulin's ability to bind to the insulin receptor, a transmembrane protein located on the surface of many cells, particularly in the liver, muscle, and adipose tissues.

​

Synthesis and Folding in the Human Body

In the human pancreas, insulin synthesis begins in the beta cells of the islets of Langerhans. The process follows several distinct stages:

  1. Preproinsulin: The initial gene transcript encodes a precursor protein known as preproinsulin. This molecule includes a signal peptide that helps guide it into the endoplasmic reticulum (ER).

  2. Proinsulin: After cleavage of the signal peptide, preproinsulin becomes proinsulin, a single polypeptide chain consisting of the A and B chains joined by a connecting peptide (C-peptide). This proinsulin is folded within the ER and the disulfide bonds are formed.

  3. Insulin: The proinsulin molecule is transported to the Golgi apparatus, where it is packaged into secretory granules. In these granules, specific enzymes cleave the C-peptide, resulting in the mature insulin molecule.

​

This biosynthetic pathway ensures that insulin has the correct shape and functional groups needed for biological activity.

​

3D Structure and Receptor Binding

Insulin's tertiary (3D) structure is essential for its biological function. The A and B chains form a compact, globular structure stabilized by hydrophobic interactions and three disulfide bonds. This structure creates a surface that fits precisely into the insulin receptor’s binding site.

​

Upon binding, the insulin receptor undergoes a conformational change that activates tyrosine kinase domains within the receptor. This leads to the phosphorylation of intracellular proteins and initiates multiple signaling pathways involved in:

  • Glucose uptake via GLUT4 translocation to the membrane

  • Glycogen synthesis

  • Protein synthesis

  • Inhibition of gluconeogenesis and lipolysis

​

Only the correctly folded insulin molecule can initiate this signaling cascade, which is why structural integrity is critical for therapeutic efficacy.

​

Hexamer Formation and Stability

In pharmaceutical formulations, insulin is often stabilized in the form of a hexamer—a structure formed by six insulin molecules that coordinate around two zinc ions.

​

  • Monomer: The active form that binds to receptors but is unstable in solution.

  • Dimer: Two insulin molecules joined together.

  • Hexamer: Six insulin monomers plus zinc; stable but inactive form.

​

Hexamer formation has practical advantages:

  • Improves storage stability

  • Prevents rapid degradation

  • Allows modulation of absorption rates upon injection

​

When injected subcutaneously, hexamers slowly dissociate into dimers and then monomers before being absorbed into the bloodstream. This property is exploited in designing intermediate-acting insulins like NPH (Neutral Protamine Hagedorn), where protamine and zinc are added to delay dissolution.

​

Modifications in Synthetic and Analog Insulin

The chemical structure of natural human insulin has been subtly modified in analog versions to achieve specific pharmacokinetic profiles. These changes involve substituting or reordering certain amino acids in the A or B chain without compromising receptor affinity.

 

For example:

  • Insulin lispro: Two amino acids at positions B28 and B29 are switched (proline and lysine), resulting in reduced self-association and faster absorption.

  • Insulin glargine: Two arginines are added to the B chain and one substitution in the A chain increases the isoelectric point, making it less soluble at physiological pH and thus absorbed more slowly.

  • Insulin detemir: Addition of a fatty acid chain allows reversible binding to albumin, extending its action duration.

​

These analogs preserve insulin’s ability to bind to receptors but alter its onset, peak, and duration to better match physiological insulin needs or simplify dosing regimens.

​

Physicochemical Properties

Insulin has several key properties that influence its formulation and delivery:

  • Solubility: Varies with pH. Soluble in acidic conditions; tends to precipitate near neutral pH.

  • Stability: Sensitive to heat, agitation, and light. Degraded by enzymes if ingested orally.

  • Isoelectric point: Around pH 5.4; formulations adjust pH to optimize solubility and stability.

 

This is why insulin is almost always injected or inhaled—oral delivery is ineffective due to digestion by proteolytic enzymes in the stomach and intestines.

​

Analytical Methods for Structural Analysis

To ensure quality and potency, insulin must be analyzed and verified using modern biochemical techniques:

  • High-Performance Liquid Chromatography (HPLC): Determines purity and content.

  • Mass Spectrometry (MS): Confirms molecular weight and sequence.

  • Circular Dichroism (CD) Spectroscopy: Assesses secondary structure.

  • X-ray Crystallography: Reveals detailed 3D conformation.

​

These techniques help manufacturers confirm that insulin batches are structurally correct and free from contaminants or misfolded variants that could impair function or provoke immune reactions.

Known Medical Applications of Insulin

Insulin is a cornerstone therapy in the treatment of diabetes and has also found selective applications in other medical conditions. Its clinical utility is driven by its ability to regulate glucose metabolism, restore glycemic balance, and prevent the acute and chronic complications of hyperglycemia.

This section explores the comprehensive role of insulin in medicine, its applications in various types of diabetes, use in critical care settings, and emerging experimental therapies.

​

Primary Indication: Diabetes Mellitus:

Type 1 Diabetes Mellitus (T1DM)

Type 1 diabetes is an autoimmune condition in which the body’s immune system attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body cannot produce insulin endogenously.

​

  • Onset: Often diagnosed in children, adolescents, and young adults, but can occur at any age.

  • Management: Requires lifelong exogenous insulin therapy.

  • Insulin role: Critical for survival. Patients typically require a basal-bolus regimen, combining long-acting and rapid-acting insulin to mimic natural secretion patterns.

  • Delivery: Often administered via multiple daily injections (MDI) or an insulin pump.

​

Without insulin, individuals with T1DM can rapidly develop diabetic ketoacidosis (DKA), a life-threatening metabolic crisis resulting from unchecked hyperglycemia and the breakdown of fats into ketones.

​

Type 2 Diabetes Mellitus (T2DM)

In contrast to type 1 diabetes, type 2 is characterized by insulin resistance—cells fail to respond properly to insulin—and an eventual decline in insulin production.

​

  • Initial management: Typically starts with lifestyle changes and oral medications such as metformin.

  • Progression: Over time, as beta-cell function diminishes, insulin may become necessary.

  • Timing: Insulin therapy in T2DM is often introduced when hemoglobin A1c levels remain elevated despite maximum oral therapy.

​

Benefits of insulin in T2DM include:

  • Reducing glucotoxicity

  • Improving beta-cell function temporarily

  • Achieving glycemic targets when other agents fail

​

Gestational Diabetes Mellitus (GDM)

Gestational diabetes occurs during pregnancy due to hormonal changes that increase insulin resistance.

​

  • Prevalence: Affects about 2–10% of pregnancies globally.

  • Treatment: Diet and exercise are first-line; insulin is introduced when lifestyle changes do not maintain target glucose levels.

  • Safety: Insulin does not cross the placenta and is considered safe for the fetus.

​

Maintaining tight glycemic control is critical to reduce the risk of preeclampsia, macrosomia, and neonatal hypoglycemia.

​

Insulin in Critical Care and Hospital Settings

Insulin has important applications in acute medical settings beyond the management of chronic diabetes. Its ability to rapidly lower blood glucose makes it essential in emergency medicine and intensive care units (ICUs).

​

Diabetic Ketoacidosis (DKA)

DKA is a medical emergency seen primarily in people with type 1 diabetes. It occurs when a lack of insulin leads to uncontrolled lipolysis and the production of acidic ketone bodies.

​

  • Symptoms: Nausea, vomiting, rapid breathing, abdominal pain, confusion.

  • Treatment: Intravenous (IV) insulin is administered alongside fluid and electrolyte replacement to correct acidosis and hyperglycemia.

  • Monitoring: Blood glucose, ketones, potassium, and pH are monitored closely.

​

Hyperosmolar Hyperglycemic State (HHS)

HHS is more common in people with type 2 diabetes and is characterized by extreme hyperglycemia, dehydration, and altered consciousness without significant ketoacidosis.

​

  • Insulin use: Administered carefully to reduce blood glucose while preventing cerebral edema.

  • Fluids: Rehydration is critical before and during insulin administration.

​

Hyperkalemia Management

Insulin is also used in the emergency treatment of hyperkalemia, a condition where potassium levels in the blood are dangerously high.

​

  • Mechanism: Insulin drives potassium into cells by stimulating the Na+/K+ ATPase pump.

  • Protocol: Typically given with glucose (e.g., 10 units of regular insulin with 25g of dextrose) to prevent hypoglycemia.

​

This application is common in renal failure, crush injuries, and certain medication toxicities.

 

Insulin in Total Parenteral Nutrition (TPN)

Patients receiving TPN (nutrition via IV) often develop hyperglycemia due to the high glucose content of the solutions.

​

  • Protocol: Regular insulin can be added directly to the TPN bag or administered separately to maintain target glucose levels.

  • Monitoring: Blood glucose is measured every 4–6 hours.

​

Hyperglycemia during TPN is associated with higher infection rates and poor outcomes, making insulin management a vital component.

​

Preoperative and Perioperative Glycemic Control

Surgical stress increases counter-regulatory hormones like cortisol and epinephrine, leading to insulin resistance and hyperglycemia.

​

  • Risk: Elevated perioperative glucose is associated with poor wound healing, infection, and increased mortality.

  • Use of insulin: Intravenous insulin infusions are commonly used to maintain glucose levels between 140–180 mg/dL during surgery.

  • Settings: Cardiac surgery, transplants, trauma, and major orthopedic procedures.

 

Experimental and Adjunctive Uses

While insulin's main role is in glucose regulation, researchers are exploring its potential in other fields:

 

Neuroprotection and Cognitive Disorders

  • Observation: Some studies suggest insulin has neuromodulatory properties and may protect against cognitive decline.

  • Application: Intranasal insulin delivery is under investigation for Alzheimer’s disease and mild cognitive impairment.

  • Mechanism: Believed to influence memory circuits and reduce neuroinflammation.

 

Polycystic Ovary Syndrome (PCOS)

  • Condition: PCOS is often associated with insulin resistance.

  • Treatment: While metformin is the first-line agent, insulin-sensitizing strategies may include basal insulin in select cases where diabetes overlaps.

 

Individualizing Insulin Therapy

Modern diabetes care emphasizes personalized insulin regimens. Factors influencing therapy decisions include:

  • Type and duration of diabetes

  • Age and lifestyle

  • Meal patterns and activity levels

  • Risk of hypoglycemia

  • Comorbid conditions

​

The choice of insulin—its formulation, dose, and timing—must be tailored to achieve glycemic goals without undue burden on the patient.

 

Key strategies:

  • Basal-bolus therapy: Simulates physiologic insulin secretion.

  • Premixed insulins: Simplify regimens in type 2 diabetes.

  • Pump therapy: Offers precision and convenience, particularly in type 1 diabetes.

  • Continuous glucose monitoring (CGM): Provides real-time data to adjust doses dynamically.

 

Insulin Dosing Guidelines

Insulin dosing is highly individualized but starts with general frameworks:

  • Type 1 diabetes: Total daily insulin dose (TDD) is ~0.4–1.0 units/kg.

    • Split 50% basal, 50% bolus.

    • Bolus doses adjusted based on carbohydrate intake and pre-meal blood sugar.

  • Type 2 diabetes: Often starts with basal insulin (e.g., 10 units or 0.2 units/kg).

    • Titrated based on fasting glucose.

    • Prandial insulin added as needed.

  • Hospital protocols: Weight-based or sliding scale regimens are used with frequent monitoring.

 

Patient education is crucial. Understanding insulin-to-carbohydrate ratios, correction factors, and recognizing symptoms of hyper- and hypoglycemia empowers patients to self-manage effectively.

​

Always discuss medications with your primary care provider before taking them. If you have any questions ask your primary care provider; this allows you to assure you're getting the care required for your unique individual health needs.

Methods of Insulin Administration

The effectiveness of insulin therapy is not only determined by the type and dosage of insulin used but also by how it is delivered into the body. Over the past century, insulin administration has evolved dramatically; from glass syringes and animal extracts to smart pumps and inhalable formulations. Modern methods aim to balance convenience, accuracy, patient lifestyle, and pharmacokinetics to optimize glycemic control and minimize complications.

​

This section covers all established and emerging methods of insulin delivery, including practical usage, pros and cons, technological innovations, and patient considerations. This information is here to help provide information but, always make sure to consult your primary care provider regarding any medical treatment.

​

1. Subcutaneous Injection

The most common and well-established route for insulin administration is the subcutaneous injection, meaning insulin is delivered into the fatty tissue beneath the skin.

​

Syringes and Vials

Traditional insulin delivery involves drawing a dose from a vial using an insulin syringe. Though less convenient compared to newer options, this method remains widely used due to its low cost and precision in dosing.

​

  • Typical needle lengths: 6mm–12mm

  • Gauge: 29G–31G

  • Available concentrations: U-100 (most common), U-200, U-300, and U-500 for high-dose needs

 

Advantages:

  • Inexpensive

  • Flexible dosing increments

 

Disadvantages:

  • Requires manual dexterity

  • Stigma and inconvenience

  • Potential for dosing errors if measurements are incorrect

 

Proper technique includes:

  • Rotating injection sites (abdomen, thighs, arms, buttocks)

  • Injecting at a 90-degree angle or 45 degrees if thin

  • Avoiding scar tissue and lipodystrophy areas

 

Insulin Pens

Insulin pens are pre-filled or refillable devices that make insulin delivery easier, more discreet, and more accurate. They resemble a large marker or pen and deliver doses in 1-unit or half-unit increments.

​

 

Advantages:

  • Portability and ease of use

  • Accurate dosing

  • Discreet in public settings

 

Disadvantages:

  • Slightly more expensive than vials

  • Limited maximum dose (usually 60–80 units per injection)

 

Insulin pens have become the dominant delivery system in many developed countries due to patient preference and reduced injection error.

 

2. Insulin Pumps

Continuous Subcutaneous Insulin Infusion (CSII), more commonly known as insulin pump therapy, delivers small amounts of insulin continuously through a catheter placed under the skin.

​

  • Basal rate: Continuous background insulin

  • Bolus dose: Mealtime or correction dose

 

Pumps typically use rapid-acting insulin (e.g., insulin lispro or aspart) and provide more physiologic insulin replacement.

 

Pump Components

  • Pump device: Controls dosing, timing, and memory

  • Infusion set: Soft cannula or steel needle inserted under the skin

  • Reservoir/cartridge: Holds insulin (usually 200–300 units)

  • Tubing: Connects the reservoir to the infusion set (unless tubeless)

 

Examples:

 

Advantages:

  • Precision in insulin delivery

  • Fewer hypoglycemia episodes

  • Flexibility in eating and exercise

 

Disadvantages:

  • High cost and insurance barriers

  • Requires extensive training

  • Risk of catheter site infections or blockages

 

Pump therapy is especially beneficial for:

  • Type 1 diabetics with unpredictable glucose swings

  • Children and adolescents

  • People with dawn phenomenon (early morning hyperglycemia)

  • Pregnant women with type 1 diabetes

 

3. Smart Insulin Delivery Systems

Modern insulin pumps are increasingly integrated with Continuous Glucose Monitors (CGMs) to create hybrid closed-loop systems, sometimes referred to as “artificial pancreases.”

These systems automatically adjust basal insulin delivery based on real-time glucose readings and can suspend insulin when blood glucose is falling, reducing the risk of hypoglycemia.

​

 

As technology advances, full closed-loop systems capable of delivering bolus doses autonomously are expected to become standard in type 1 diabetes care.

 

4. Inhalable Insulin

Technosphere Insulin (Afrezza®) is an FDA-approved, ultra-rapid acting inhaled insulin powder.

  • Delivered through a handheld inhaler at the beginning of a meal

  • Peaks in ~12–15 minutes

  • Duration: 2–3 hours

 

Indications:

  • Mealtime glucose control

  • Used in combination with long-acting injectable insulin

 

Advantages:

  • Needle-free

  • Very fast onset

  • Reduces injection burden

​

Disadvantages:

  • Not suitable for people with asthma or COPD

  • Requires pulmonary function testing before prescription

  • Cost and availability can be limiting

 

Inhaled insulin offers a viable alternative for needle-averse individuals and may be particularly useful in noncompliant patients or those seeking more lifestyle flexibility.

 

5. Jet Injectors

Jet injectors deliver insulin through a high-pressure stream that penetrates the skin without a needle. They use mechanical or gas-powered systems to disperse insulin into the subcutaneous tissue.

 

Pros:

  • Completely needle-free

  • Useful for patients with needle phobia

 

Cons:

  • Pain or bruising at the injection site

  • Variable absorption

  • Bulky devices and lack of popularity

 

While promising, jet injectors are rarely used due to cost, discomfort, and dosing inconsistency.

 

6. Intravenous (IV) Insulin

Used almost exclusively in hospital or critical care settings, IV insulin is the fastest-acting delivery method. It is administered via an infusion pump in settings such as:

  • Diabetic ketoacidosis

  • Surgery and perioperative glucose management

  • Sepsis or critical illness-related hyperglycemia

 

Regular insulin is the only type used intravenously. Because of its potency and risk of hypoglycemia, IV insulin requires continuous monitoring, typically every 30–60 minutes.

 

7. Intramuscular (IM) Injection

While not routinely used, intramuscular insulin delivery has a faster onset than subcutaneous injection due to rich blood supply in muscle tissue.

  • Rarely indicated

  • Risk of absorption variability and hypoglycemia

  • May occur accidentally if subcutaneous technique is incorrect

 

Modern practice discourages IM use unless under strict supervision or in emergencies.

 

8. Intranasal and Buccal Insulin (Under Research)

Research into mucosal delivery routes—including intranasal and buccal (inner cheek) insulin—is ongoing.

  • Intranasal insulin is being studied not just for diabetes but for potential use in Alzheimer’s and cognitive disorders.

  • Buccal delivery systems aim to allow insulin to be absorbed through the mouth lining, avoiding degradation by stomach acid.

 

These methods hold promise for non-invasive insulin therapy but require breakthroughs in absorption efficiency and bioavailability.

 

Site Rotation and Injection Technique

Regardless of the delivery method, proper technique ensures consistent absorption and prevents complications such as:

  • Lipohypertrophy: Lump formation under the skin from repeated injections at the same site

  • Lipoatrophy: Fat tissue loss, less common with newer insulins

 

Injection sites:

  • Abdomen (fastest absorption)

  • Thighs and buttocks (slower)

  • Arms

 

Rotating sites within each region helps maintain predictable absorption and reduces tissue damage.

 

Choosing the Right Delivery Method

Several factors influence which method is best suited for a particular individual:

  • Age and dexterity

  • Type of diabetes

  • Lifestyle and occupation

  • Fear of needles

  • Financial and insurance considerations

  • Availability of technology

 

Patients should be educated on all available methods and empowered to choose the one that aligns best with their life.

 

Training and Education

Proper training is essential for safe and effective insulin administration. Education typically includes:

  • How to read insulin labels and understand concentrations (e.g., U-100 vs U-500)

  • How to calculate doses and insulin-to-carb ratios

  • Use of CGM and interpreting data

  • Managing hypoglycemia and hyperglycemia

​

Diabetes educators and endocrinology specialists play a crucial role in guiding patients through this process. Make sure you consult your primary care provider to assess what is best for your personal health. Your primary care provider will help you determine what treatments work for you.

Possible Side Effects of Insulin

While insulin is a life-saving and essential therapy for millions of people with diabetes, it is not without its potential side effects. Understanding these side effects is critical for both patients and healthcare professionals in order to maximize insulin's therapeutic benefit while minimizing harm.

This section explores the spectrum of side effects associated with insulin therapy—from the most common and well-known complications like hypoglycemia, to rarer but clinically significant issues like lipodystrophy, allergic reactions, and weight gain. Additionally, it discusses the causes, risk factors, prevention strategies, and management of these effects. It's important to discuss any possible side effects with your primary care provider.

​

1. Hypoglycemia (Low Blood Glucose)

Hypoglycemia is the most serious and common side effect of insulin therapy. It occurs when insulin lowers blood glucose to levels below 70 mg/dL (3.9 mmol/L), although symptoms may vary depending on the individual and their baseline control.

​

Symptoms of Mild to Moderate Hypoglycemia:

  • Shaking or tremors

  • Sweating

  • Palpitations

  • Anxiety or irritability

  • Hunger

  • Dizziness or lightheadedness

  • Blurred vision

​

Severe Hypoglycemia:

Occurs when blood glucose falls low enough to impair brain function, leading to:

  • Confusion

  • Slurred speech

  • Unconsciousness

  • Seizures

  • Death (in extreme, untreated cases)

​

Incidence:

  • In type 1 diabetes, studies show the average patient experiences 1–2 episodes of symptomatic hypoglycemia per week and at least one severe episode per year.

  • In type 2 diabetes, the risk increases with insulin use duration, especially in older adults or those with renal impairment.

​

Risk Factors:

  • Excessive insulin doses

  • Skipping meals or delaying food intake

  • Alcohol consumption

  • Increased physical activity without insulin adjustment

  • Renal or hepatic impairment

  • Poor insulin timing or incorrect type (e.g., rapid vs. long-acting)

​

Prevention and Management:

  • Regular self-monitoring of blood glucose (SMBG) or continuous glucose monitoring (CGM)

  • Dose titration based on meals and activity

  • Emergency treatment: 15g of fast-acting carbohydrates (e.g., glucose tablets or juice)

  • Glucagon injection or nasal glucagon for unconscious patients

​

2. Weight Gain

Insulin therapy often leads to weight gain, particularly in patients initiating insulin for the first time or increasing doses.

​

Mechanism:

  • Anabolic effects: Insulin promotes fat storage and protein synthesis.

  • Reduced glycosuria: Before insulin, excess glucose is lost in urine; insulin allows glucose to enter cells, adding to caloric retention.

  • Defensive eating: Fear of hypoglycemia may lead to overconsumption of snacks.

 

Prevalence:

  • Average weight gain after starting insulin therapy is 4–6 kg (8.8–13.2 lbs) in the first year.

  • More pronounced in type 2 diabetes than in type 1.

 

Prevention:

  • Use of basal insulin analogs with lower hypoglycemia risk

  • Combined therapy with GLP-1 receptor agonists or SGLT2 inhibitors, which are weight-neutral or cause weight loss

  • Structured diet and exercise programs

 

3. Lipodystrophy

Lipodystrophy refers to abnormal changes in fat tissue at injection sites, which can impact insulin absorption and glycemic control.

​

Types:

  • Lipohypertrophy: Buildup of fat under the skin, appearing as lumps or bumps

  • Lipoatrophy: Loss of subcutaneous fat, creating pitted areas (rare with modern insulin)

 

Causes:

  • Repeated injections at the same site

  • Use of cold insulin or contaminated needles

  • Local inflammatory or immune responses

 

Prevalence:

  • Lipohypertrophy affects up to 50% of insulin users, especially those who do not rotate sites regularly.

 

Impact:

  • Insulin injected into lipohypertrophic tissue may absorb unpredictably, leading to glycemic variability and more frequent hypoglycemia.

 

Prevention:

  • Rotate injection sites

  • Inspect skin regularly

  • Use a new needle for every injection

 

4. Allergic Reactions

Insulin allergy is rare but can occur. Reactions may range from mild local irritation to systemic anaphylaxis.

​

Local Reactions:

  • Redness, itching, or swelling at the injection site

  • Usually resolve without intervention

 

Systemic Reactions:

  • Generalized rash

  • Angioedema

  • Shortness of breath

  • Anaphylaxis (very rare)

 

Risk Factors:

  • Impurities in early animal-derived insulin (modern recombinant insulin has far fewer reactions)

  • Sensitivity to preservatives like metacresol or phenol

 

Management:

  • Switch to a different insulin formulation

  • Use antihistamines or corticosteroids for moderate cases

  • Desensitization protocols under allergist supervision for severe reactions

 

5. Insulin Resistance

While most patients with type 2 diabetes already have some degree of insulin resistance, long-term high-dose insulin therapy may lead to acquired resistance, requiring even higher doses to achieve control.

 

Contributors:

  • Obesity

  • Sedentary lifestyle

  • Chronic inflammation

  • Lipohypertrophy

 

Consequences:

  • Exacerbates hyperglycemia

  • Encourages weight gain

  • Increases insulin costs

 

Strategies:

  • Weight loss

  • Exercise

  • Addition of insulin sensitizers (e.g., metformin, pioglitazone)

  • Switching to concentrated insulins (U-500) to reduce injection volume

 

6. Edema

Some patients experience peripheral edema after starting or increasing insulin doses. This fluid retention is typically mild and transient.

 

Mechanism:

  • Sodium retention in kidneys

  • Vasodilation effects of insulin

 

Presentation:

  • Swelling in ankles or legs

  • Puffy hands or feet

 

Resolution:

  • Typically self-limited

  • May require dose adjustment or diuretics in persistent cases

 

7. Hypokalemia

Insulin drives potassium from the blood into cells, which can lead to low serum potassium levels; particularly when insulin is given intravenously.

 

Symptoms:

  • Muscle weakness or cramps

  • Arrhythmias

  • Fatigue

 

Precaution:

  • Potassium monitoring is essential during IV insulin therapy in DKA or HHS

  • Supplementation may be required if levels drop below 3.5 mmol/L

 

8. Antibody Formation

In rare cases, patients develop anti-insulin antibodies that bind insulin and interfere with its action.

 

Clinical Effects:

  • Unpredictable insulin response

  • Recurrent hyper- or hypoglycemia

 

Who’s at Risk:

  • Higher incidence with animal insulins (now rarely used)

  • Some immunologic conditions

 

Management:

  • Switching to analog insulin

  • Use of immunosuppressive agents (e.g., steroids) in severe cases

  • Plasmapheresis in extreme situations

 

9. Injection Site Pain or Bruising

Injection discomfort is usually minor but can affect adherence.

 

Common Causes:

  • Cold insulin

  • Incorrect technique

  • Repeated use of blunt needles

 

Tips to Reduce Pain:

  • Allow insulin to reach room temperature before injecting

  • Use shorter and finer-gauge needles

  • Insert quickly and remove smoothly

 

10. Rare and Long-Term Complications

Though rare, long-term insulin use has been studied for associations with:

  • Cancer risk: Early concern with glargine insulin; large studies show no significant increase in cancer risk with any insulin type.

  • Retinopathy progression: Rapid glucose lowering can temporarily worsen diabetic retinopathy, particularly in poorly controlled patients; long-term outcomes are protective.

 

These concerns are monitored but have not been conclusively linked to insulin therapy when appropriately managed.

Benefits of Insulin Use 

Though insulin therapy may be associated with side effects and challenges, its benefits are profound and often life-saving. For people with diabetes—particularly those with type 1 and advanced type 2—insulin is not merely a drug; it is a foundational treatment that restores metabolic function and prevents both short- and long-term complications. Its positive effects span physiological, psychological, and socioeconomic dimensions, improving patient outcomes and reducing healthcare burdens.

This section examines the multifaceted benefits of insulin therapy, ranging from biochemical improvements to enhanced quality of life and disease prevention. As always discuss any medical treatment with your primary care provider.

​

1. Life-Saving Therapy in Type 1 Diabetes

Perhaps the most undeniable benefit of insulin is its role as a life-sustaining treatment for individuals with type 1 diabetes mellitus (T1DM). Prior to its discovery in the 1920s, T1DM was universally fatal. Patients, often children, succumbed to diabetic ketoacidosis (DKA) within weeks or months of diagnosis. The only temporary treatment was a starvation diet, which delayed death but led to severe malnutrition.

With the advent of insulin:

  • Survival became possible for the first time

  • Children could grow, attend school, and live normal lives

  • Adult patients could return to work, support families, and contribute to society

 

Today, with proper insulin management, individuals with T1DM can achieve near-normal life expectancy and participate fully in education, sports, and careers.

 

2. Improved Glycemic Control

The primary therapeutic goal in diabetes is to maintain blood glucose levels as close to normal as possible. Insulin is the most effective agent for achieving this goal because it directly facilitates glucose uptake and utilization by the body’s cells.

 

Impact on Glycemic Metrics:

  • Reduces fasting and postprandial glucose levels

  • Lowers hemoglobin A1c (HbA1c), a long-term measure of glucose control

  • Limits glycemic variability and excursions

 

Studies such as the Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS) demonstrated that tight glycemic control via insulin significantly reduces the risk of microvascular complications.

 

3. Prevention of Acute Complications

Exogenous insulin prevents the onset of serious acute complications such as:

  • Diabetic ketoacidosis (DKA): A life-threatening condition caused by insulin deficiency leading to ketosis and acidosis

  • Hyperosmolar hyperglycemic state (HHS): Common in type 2 diabetes with extreme hyperglycemia and dehydration

  • Hyperglycemia-induced dehydration: Frequent urination and fluid loss can lead to shock in unmanaged diabetes

 

These emergencies require rapid insulin administration for resolution and prevention of organ damage or death.

 

4. Prevention of Chronic Complications

Long-standing hyperglycemia causes damage to blood vessels and nerves, resulting in chronic complications that can severely impact quality of life. Effective insulin therapy has been shown to prevent or delay the onset of:

  • Retinopathy (vision loss due to damage to the retinal vessels)

  • Nephropathy (kidney disease leading to dialysis or transplant)

  • Neuropathy (nerve damage causing pain, numbness, or gastroparesis)

  • Cardiovascular disease (heart attacks, strokes)

 

The DCCT study found a 76% reduction in retinopathy progression with intensive insulin therapy in type 1 diabetes, while the UKPDS showed improved cardiovascular outcomes in type 2 patients.

 

5. Flexibility in Dietary Choices

Modern insulin regimens, especially with the use of rapid-acting analogs and insulin pumps, offer patients the flexibility to adjust their insulin dose based on carbohydrate intake.

This allows individuals to:

  • Eat at variable times

  • Enjoy a broader range of foods

  • Manage spontaneous activities like travel or exercise

 

This is particularly important for children, adolescents, and active adults, where rigid schedules may be impractical.

 

6. Enhanced Quality of Life

Proper insulin management reduces the frequency and severity of diabetes symptoms, such as:

  • Excessive thirst

  • Frequent urination

  • Blurred vision

  • Fatigue

  • Poor wound healing

 

By stabilizing glucose levels, patients experience improved energy, concentration, and emotional well-being.

​

Furthermore, the availability of convenient delivery systems like insulin pens, smart pumps, and CGMs makes insulin therapy more discreet, less painful, and easier to integrate into daily routines.

 

7. Reduced Healthcare Costs from Complications

Although insulin itself can be expensive, especially in the United States. Its proper use reduces long-term healthcare costs by preventing costly complications.

 

For example:

  • Treating end-stage renal disease (ESRD) with dialysis can cost $90,000+ per year

  • Amputation due to diabetic foot ulcers leads to long-term rehabilitation and prosthetics

  • Hospitalization for DKA or HHS is often over $20,000 per episode

 

By maintaining glycemic control, insulin reduces hospitalization, surgeries, and emergency visits, ultimately lowering overall system expenditures.

 

8. Adaptability to All Stages of Diabetes

Insulin is the only treatment universally applicable to all stages and types of diabetes:

  • Type 1: From diagnosis onward

  • Type 2: When oral agents and non-insulin injectables no longer suffice

  • Gestational: Safe during pregnancy

  • Secondary diabetes: Due to pancreatitis, steroids, or endocrine disorders

 

It can be customized as:

  • Basal therapy: Once-daily background insulin

  • Bolus therapy: Mealtime insulin for postprandial control

  • Premixed therapy: For convenience in type 2 diabetes

  • Pump therapy: For precision and automation in type 1 diabetes

 

This makes insulin a cornerstone of individualized treatment plans.

 

9. Synergy with Other Therapies

Insulin can be used alone or in combination with other antidiabetic agents, including:

  • Metformin

  • SGLT2 inhibitors

  • GLP-1 receptor agonists

  • DPP-4 inhibitors

 

This synergistic approach:

  • Enhances glycemic control

  • Reduces insulin dose requirements

  • Lowers risk of hypoglycemia and weight gain

  • Offers cardioprotective or renal-protective effects (with certain combinations)

 

10. Empowerment Through Technology

Advancements in insulin-related technologies have empowered patients like never before:

  • Smart insulin pens track doses and sync with smartphone apps

  • CGM-integrated pumps automate insulin delivery

  • Decision-support software helps adjust doses based on trends

 

These innovations not only improve glucose metrics but increase patient confidence and engagement in their own care.

​​

​

Insulin therapy remains the most powerful and versatile tool in diabetes management. Its benefits extend far beyond glucose control, touching every aspect of patient health, from acute survival to long-term wellness. As delivery methods improve and patient education expands, insulin continues to enhance lives with the promise of a healthier, fuller future for people with diabetes. Always discuss any medical treatments with your primary care provider. This helps make sure your get the treatment that is best for your personal health.

Innovations in Insulin Delivery & Development

Over the past century, insulin has undergone dramatic transformations; not only in how it’s made but also in how it’s delivered, absorbed, and controlled. From animal pancreas extracts to smart pumps and gene therapy research, insulin stands as a model of medical innovation. Driven by patient demand, technological progress, and biotechnology breakthroughs, the modern landscape of insulin therapy is evolving rapidly toward greater personalization, automation, and accessibility.

​

This section explores cutting-edge developments in insulin formulation, delivery systems, smart devices, and experimental therapies shaping the future of diabetes care.

​

1. Insulin Analogs with Customized Action Profiles

One of the most transformative innovations in insulin development has been the creation of insulin analogs; genetically modified insulins with specific alterations to their amino acid sequence. These modifications change how insulin behaves in the body, allowing for faster or longer action compared to human insulin.

​

Types of Analog Insulin:

  • Rapid-acting:

    • Examples: Lispro (Humalog), Aspart (NovoLog), Glulisine (Apidra)

    • Action begins within 10–20 minutes and peaks around 1 hour

    • Ideal for mealtime boluses

  • Long-acting:

    • Examples: Glargine (Lantus), Detemir (Levemir), Degludec (Tresiba)

    • Mimic basal insulin secretion with minimal peaks

    • Provide 24–42 hours of steady coverage

  • Ultra-rapid and ultra-long acting:

    • Examples: Faster Aspart (Fiasp), Concentrated Glargine (Toujeo)

    • Offer even more refined control, flexibility in timing, and fewer hypoglycemic episodes

 

These analogs improve quality of life by more closely replicating physiologic insulin needs and reducing risks of both hyper- and hypoglycemia.

 

2. Smart Insulin (Glucose-Responsive Insulin)

One of the most exciting areas of innovation is the development of smart insulin, or glucose-responsive insulin (GRI). These formulations are designed to automatically adjust their activity based on the blood glucose level; mimicking the body’s natural feedback system.

 

How It Works:

  • The insulin is combined with a glucose-sensitive polymer or molecule.

  • When glucose levels rise, the insulin is released or activated.

  • When levels fall, the release stops, reducing the risk of hypoglycemia.

 

Benefits:

  • Eliminates the need for multiple daily injections

  • Reduces hypoglycemia risk

  • Simplifies diabetes management

 

GRI is currently in preclinical and early clinical trial phases. Companies like Novo Nordisk and MIT-based startups are leading research efforts.

 

3. Artificial Pancreas Systems

Artificial pancreas systems represent the frontier of automated diabetes care. These systems integrate three main components:

  1. Continuous Glucose Monitor (CGM)

  2. Insulin Pump

  3. Algorithmic Controller (software or app)

 

Together, they form a closed-loop insulin delivery system, automatically adjusting insulin doses based on real-time glucose readings.

 

Examples in Market:

 

Advantages:

  • Increases time-in-range (glucose between 70–180 mg/dL)

  • Reduces A1c levels

  • Minimizes nocturnal hypoglycemia

  • Less burden of decision-making

 

Artificial pancreas systems are especially beneficial for type 1 diabetes and are rapidly becoming the standard of care for technologically adept users.

 

4. Connected Smart Devices

The rise of connected health devices is making insulin delivery smarter, more accurate, and easier to track.

 

Smart Pens:

  • Insulin pens that automatically log injection time, date, and dose

  • Sync with smartphone apps for reminders and dose tracking

  • Examples: InPen, NovoPen 6, Tempo Pen

 

Bluetooth CGMs and Apps:

  • CGMs like Dexcom G7, Freestyle Libre 3, and Guardian Sensor 4 transmit real-time data to mobile devices

  • Predictive alerts help users avoid dangerous glucose levels

  • Integration with health tracking apps allows full visibility and analytics

 

These devices not only improve outcomes but enhance patient autonomy and adherence.

 

5. Oral and Buccal Insulin Delivery

For decades, researchers have sought a way to deliver insulin orally, bypassing needles altogether. The challenge lies in insulin’s protein structure, which is easily degraded by stomach acid and digestive enzymes.

 

Solutions Under Study:

  • Encapsulation in nanoparticles that resist digestion

  • Coating with enzyme inhibitors or absorption enhancers

  • Mucoadhesive tablets that stick to the intestinal lining

 

Some pharmaceutical companies, such as Oramed Pharmaceuticals, have ongoing clinical trials for oral insulin capsules.

 

Buccal insulin (absorbed through the inner cheek) is another approach, being studied for faster absorption and ease of use, though bioavailability challenges remain.

 

6. Needle-Free Jet Injectors

Jet injectors use high-pressure air or spring-loaded devices to push insulin through the skin without a needle.

​

 

While not mainstream, these devices may appeal to people with severe needle phobia or children.

 

7. Implantable Insulin Pumps

An emerging area of research is implantable insulin pumps, which deliver a controlled, programmable flow of insulin directly into the peritoneal cavity.

​

  • Placed under the skin with a catheter directed toward the abdomen

  • Refilled every 40–60 days by healthcare providers

  • Benefits: Highly precise dosing, fewer infections, stable absorption

 

Though still in development and used mostly in clinical studies, implantable pumps may become viable options for people with extreme insulin sensitivity or brittle diabetes.

 

8. Microneedle Patches

Microneedle patches are thin patches embedded with dozens of tiny, painless needles that deliver insulin transdermally.

 

Key Features:

  • Needles are so small they don’t activate pain receptors

  • Deliver insulin into the dermis, avoiding gastrointestinal degradation

  • Potential to carry glucose sensors as well for smart delivery

 

Duke University and University of North Carolina researchers have pioneered microneedle patches in animals, and human trials are expected soon.

 

9. Gene Therapy and Cell-Based Approaches

The holy grail of diabetes treatment is curing the disease at its root—by restoring the body’s ability to produce insulin naturally.

 

Pancreatic Islet Cell Transplants:

  • Involves transplanting beta cells from donors into patients

  • Requires immunosuppressive therapy

  • Still experimental, but shown promise in reducing or eliminating insulin needs

 

Stem Cell-Derived Beta Cells:

  • Companies like Vertex Pharmaceuticals and ViaCyte (now owned by Vertex) are developing ways to produce insulin-producing cells from stem cells

  • Some trials show patients producing insulin endogenously for months

 

Gene Editing (CRISPR):

  • Early research aims to correct genetic defects in beta cells or reprogram other cells to secrete insulin

  • Still years away from clinical use but offers long-term hope

 

10. Biosimilar Insulins and Global Access

The development of biosimilar insulins follow-on products to branded biologics offers a more affordable alternative, especially in low- and middle-income countries.

 

Approved Biosimilars:

  • Basaglar (biosimilar to Lantus)

  • Semglee (FDA-approved interchangeable biosimilar to glargine)

  • Admelog (biosimilar to Humalog)

 

Impact:

  • Cost savings of 15–30% compared to originals

  • Expanding access to insulin globally

  • Encouraging competitive pricing

 

However, barriers remain in regulatory approval, patient trust, and distribution logistics, particularly in underserved regions.

​​

​

Innovations in insulin therapy are rapidly reshaping diabetes management. With advances in molecular engineering, artificial intelligence, drug delivery, and regenerative medicine, insulin is moving from being a manual, one-size-fits-all therapy to a personalized, automated, and smarter treatment.

 

These innovations promise to:

  • Improve outcomes

  • Reduce treatment burden

  • Increase global access

  • Ultimately move us closer to a future where diabetes can be managed with minimal disruption to life, or potentially cured altogether.

Insulin Global Statistics & Insulin Usage Trends

As the burden of diabetes increases worldwide, insulin demand continues to rise. Understanding who uses insulin, how it is distributed globally, and where the most pressing challenges lie is crucial to developing policies and innovations that improve access and outcomes. This section offers a detailed, data-driven view of global insulin usage trends, country-specific statistics, demographic factors, and economic impacts of insulin therapy.

​

1. Global Diabetes Prevalence

According to the International Diabetes Federation (IDF) Diabetes Atlas (10th edition, 2021), diabetes affects:

  • 537 million adults (20–79 years) worldwide

  • Expected to reach 643 million by 2030, and 783 million by 2045

  • Over 6.7 million deaths annually related to diabetes and its complications

  • Almost half of all people with diabetes are undiagnosed

 

Though not all diabetics require insulin, a significant proportion—particularly those with type 1 diabetes and advanced type 2 diabetes—depend on it for survival and metabolic control.

 

2. Estimated Global Insulin Users

Approximately 100–150 million people worldwide use insulin therapy, though precise data is difficult to ascertain due to inconsistent reporting and access disparities. A 2019 study published in The Lancet Diabetes & Endocrinology projected:

  • 79 million people with type 2 diabetes would require insulin by 2030

  • 40 million additional users from type 1 diabetes, gestational diabetes, and hospital-based care

  • Greater unmet needs in Africa, Asia, and Latin America due to cost and infrastructure

 

Insulin demand is increasing at 6–8% annually, outpacing population growth and healthcare expansion in many regions.

 

3. Country-Specific Statistics

China

  • Largest number of people with diabetes: 141 million adults

  • Rapid urbanization and dietary shifts contribute to high incidence

  • Over 40 million people estimated to require insulin

  • Market dominated by domestic and international companies (Novo Nordisk, Tonghua Dongbao)

 

India

  • Second-highest diabetes population: 77 million (expected to surpass China by 2045)

  • Low-cost biosimilars widely used

  • Major access gaps in rural areas; insulin affordability remains a key issue

 

United States

  • Roughly 37 million people with diabetes

  • 8.4 million Americans use insulin (CDC, 2022)

  • High insulin prices: average retail price ~$98 per vial in 2019

  • Ongoing legislative efforts to cap prices and expand access (e.g., Inflation Reduction Act insulin cap at $35 for Medicare recipients)

 

Europe

  • Western Europe has one of the highest type 1 diabetes rates globally

  • Germany, UK, and France lead in insulin users and biosimilar adoption

  • Public insurance systems improve access; biosimilar uptake helps contain costs

 

Sub-Saharan Africa

  • Low prevalence compared to developed nations (~24 million cases), but highest growth rate

  • Insulin access remains critically low, many patients die within a year of type 1 diabetes diagnosis

  • WHO, Life for a Child, and MSF working to provide insulin at subsidized rates

 

4. Insulin Supply and Manufacturers

The insulin supply chain is highly consolidated. Three multinational companies; Novo Nordisk, Sanofi, and Eli Lilly produce over 90% of the world’s insulin supply (particularly in analog formulations).

 

Top Insulin Producers:

 

Biosimilar Growth:

  • Biosimilars offer an opportunity for cost reduction

  • Markets in India, Brazil, China, Russia, and South Africa are emerging as regional producers

 

While biosimilars are gaining ground, regulatory hurdles, clinician bias, and supply chain limitations hamper global equity.

 

5. Disparities in Access and Affordability

Insulin access is grossly unequal across different parts of the world. According to WHO:

  • One in two people who need insulin cannot reliably access it

  • In low-income countries, a month's supply of insulin can cost over 30% of a household’s disposable income

  • Cold chain requirements limit insulin distribution in areas without stable electricity

 

Price variability is another major concern (Country Avg Cost per Vial (U-100) & Access Challenges):

United States - $98 USD (before insurance) with high list prices and co-pays.

UK - $0–$10 USD with NHS covering cost.

India - $4–$10 USD (biosimilars) with Quality variation, rural shortages.

Kenya - $18–$25 USD with Limited cold storage and import costs.

Venezuela - Highly variable with Supply disruptions and currency issues.

 

6. Insulin Use in Hospitals and Critical Care

Insulin use isn’t limited to outpatient diabetes care. In hospitals, it plays a critical role in:

  • Managing hyperglycemia in critically ill patients

  • Treating diabetic ketoacidosis and hyperosmolar states

  • Controlling glucose during total parenteral nutrition

  • Maintaining perioperative glucose targets

 

According to a 2020 analysis published in Critical Care Medicine:

  • Up to 30% of ICU patients receive insulin

  • Hospital protocols often involve intravenous insulin infusions and frequent glucose monitoring

  • Glucose control in hospital settings is associated with lower infection rates and shorter stays

 

7. Insurance and Insulin Reimbursement Policies

United States:

  • Insulin is covered under private insurance, Medicare, and Medicaid, but out-of-pocket costs can still be substantial

  • Some states have passed laws capping insulin copays (e.g., Illinois, Colorado, California)

  • Federal policy as of 2023 caps Medicare Part D insulin at $35/month

 

Europe:

  • Universal coverage in most countries

  • High biosimilar uptake reduces government spending

 

Developing Countries:

  • Inconsistent or non-existent insurance coverage

  • Reliance on donor programs (e.g., WHO's Global Diabetes Compact)

 

Policy changes are critical to scaling access and reducing mortality from diabetes-related complications.

 

8. Gender, Age, and Socioeconomic Trends

Gender:

  • Women in low-income settings often face greater barriers to insulin access

  • Pregnancy-related diabetes (GDM) increases the burden

 

Age:

  • Type 1 diabetes often manifests in children and adolescents

  • Rising type 2 cases among youth linked to obesity epidemics

  • Elderly patients at risk for hypoglycemia and poor adherence due to polypharmacy

 

Income Disparity:

  • Wealthier populations can afford analog insulins, pumps, and CGMs

  • Poorer populations often rely on older formulations, limited testing, and inconsistent care

 

These factors compound and drive disparities in outcomes across and within countries.

 

9. Global Health Initiatives and Future Goals

Organizations working to improve global insulin access:

  • World Health Organization (WHO): Added insulin analogs to the Essential Medicines List (2021), pushing for broader access and price transparency

  • Life for a Child: Provides insulin and diabetes supplies to children in 43+ countries

  • UNICEF & MSF: Work on cold chain delivery in conflict zones

  • Global Diabetes Compact: Launched by WHO in 2021 to align governments, civil society, and private sectors

 

2030 goals include:

  • Universal access to affordable insulin

  • Doubling global diagnosis and treatment coverage

  • Increasing biosimilar approval and integration in national formularies

 

10. Economic Impact of Insulin Therapy

The global diabetes cost in 2021 was estimated at $966 billion, up 316% from 2007. Insulin therapy constitutes a significant portion of direct medical expenses, especially in:

  • Hospitalizations for hypoglycemia or DKA

  • Managing complications from poor glucose control

  • Long-term medication and supply costs

 

However, when used effectively, insulin can drastically reduce:

  • Long-term health care costs

  • Disability-adjusted life years (DALYs)

  • Lost productivity due to illness

 

Return on investment studies show that every $1 USD spent on insulin access can save $4–$10 USD in complication-related expenses.

The Future of Insulin & Diabetes Management

The future of insulin therapy lies at the intersection of biotechnology, data science, policy reform, and personalized medicine. While insulin will likely remain a cornerstone of diabetes care for decades, ongoing innovation aims not just to improve its delivery; but to minimize dependence on it altogether, and possibly one day eliminate the need for it entirely through curative therapies.

​

This section explores emerging breakthroughs, visionary research, and systemic shifts that may define the next chapter of insulin and diabetes management.

​

1. Toward a Functional Cure: Beta Cell Regeneration and Transplantation

The most ambitious goal in diabetes research is a cure—not merely managing blood sugar, but restoring the body’s own ability to produce insulin.

​

Stem Cell–Derived Islet Cells:

  • Researchers are developing pluripotent stem cells (PSCs) that can be differentiated into insulin-producing beta cells.

  • Vertex Pharmaceuticals (VX-880 trial) has shown early success: patients with type 1 diabetes have reduced or even eliminated their insulin use after receiving encapsulated beta cell transplants.

  • ViaCyte, a biotech company (purchased by Vertex), is developing implantable devices that shield stem cells from immune attack.

 

Encapsulation Technology:

  • To avoid immunosuppression, scientists are designing biocompatible capsules that house transplanted cells while shielding them from immune rejection.

  • Trials in Canada, the U.S., and Europe are exploring this with encouraging early results.

 

Challenges:

  • Immune rejection

  • Long-term graft survival

  • Cost and scalability

 

2. Gene Therapy and Editing Technologies

Gene therapy offers the possibility of rewiring the pancreas or reprogramming other cells in the body to produce insulin.

 

Approaches in Development:

  • CRISPR/Cas9 editing: Corrects autoimmune triggers or genetic defects in beta cells.

  • Liver or gut cell reprogramming: Converts these abundant, insulin-insensitive cells into ones capable of secreting insulin.

  • Immunotherapy: Stops the autoimmune attack that causes type 1 diabetes before it destroys all beta cells.

 

Though still in early stages, gene therapy could be a long-term, one-time treatment rather than daily injections for life.

 

3. Closed-Loop and AI-Driven Systems

The integration of artificial intelligence (AI) with diabetes technology is transforming care from reactive to predictive and automated.

 

Next-Generation Artificial Pancreas Systems:

  • Closed-loop systems that not only adjust insulin but also anticipate needs based on patterns of meals, activity, sleep, and stress.

  • Adaptive algorithms that learn individual glucose responses and optimize insulin delivery in real time.

 

Predictive Alerts:

  • AI tools analyzing CGM data can now warn patients before hypo- or hyperglycemia occurs, improving safety.

 

Voice- and app-based coaching tools:

  • AI-powered health assistants (e.g., Livongo, Omada, mySugr) offer tailored advice, medication reminders, and behavioral nudges.

 

The more data these systems integrate food logs, heart rate, sleep; the more they can deliver truly personalized insulin therapy.

 

4. Ultra-Stable and Temperature-Resistant Insulins

One of the barriers to insulin access in lower-income and remote regions is the cold chain, the need to refrigerate insulin to prevent degradation.

Researchers are developing thermostable insulin formulations that can withstand higher ambient temperatures without losing potency.

 

Notable Advances:

  • BioChaperone insulin: Uses stabilizing agents to preserve efficacy even above 40°C (104°F).

  • Refrigeration-free insulin pens in development by nonprofit pharma partnerships.

 

Such formulations could revolutionize access in tropical climates, humanitarian settings, and areas without electricity.

​

5. Oral, Nasal, and Transdermal Delivery

Insulin delivery is becoming less invasive and more convenient.

  • Oral insulin: Companies like Oramed Pharmaceuticals are developing capsules with enzyme-resistant coatings.

  • Nasal insulin: Potential for both rapid glucose control and cognitive effects (studied for Alzheimer’s disease).

  • Microneedle patches: Offer painless, precise transdermal delivery with potential for mass production.

 

These methods will lower barriers to therapy initiation and improve adherence.

 

6. Policy and Access Innovation

The future of insulin isn’t only technological—it’s also socio-political. Policy shifts are underway to make insulin more affordable, transparent, and universally accessible.

 

Examples of Policy Reform:

  • Insulin price caps in U.S. states and Medicare ($35USD/month max).

  • WHO Essential Medicines List expansion to include analog insulins.

  • Tiered pricing models from insulin manufacturers for low-income countries.

 

The push for insulin equity is gaining momentum through international alliances, including the Global Diabetes Compact launched by WHO in 2021.

 

7. Decentralized Manufacturing and Biosimilars

In the coming years, expect more regional insulin production facilities using biosimilar technologies to serve local markets at lower costs.

​

  • Modular insulin factories that can operate in smaller countries

  • Technology transfer from large manufacturers to generic drugmakers

  • WHO Prequalification Programs to ensure safety and efficacy

 

This decentralization would boost supply resilience and reduce reliance on global shipping and cold storage networks.

​

8. Integration with Broader Metabolic Care

As understanding of diabetes evolves, insulin management is increasingly being integrated into whole-person care approaches:

  • Weight management through adjunct therapies (e.g., GLP-1s)

  • Cardio-renal protection with SGLT2 inhibitors

  • Behavioral health support for diabetes distress and burnout

 

The future of insulin therapy is interdisciplinary, involving endocrinologists, cardiologists, dietitians, mental health professionals, and digital health coaches.

 

9. Democratization of Diabetes Data

With the spread of smartphones, wearables, and cloud-connected health devices, individuals are gaining unprecedented control over their insulin management.

​

  • Open-source tools like OpenAPS and Loop allow patients to build their own DIY closed-loop systems.

  • Platforms like Tidepool, Apple Health, and Dexcom Clarity; aggregate and visualize data for easier decision-making.

 

Patients can now be co-pilots rather than passengers in their care.

 

10. A Future Without Daily Insulin?

The ultimate vision for the future is a world where daily insulin injections are no longer necessary:

  • Immunotherapy to halt autoimmune destruction of beta cells

  • Preventative vaccines for type 1 diabetes (in clinical trials)

  • One-time gene edits to cure insulin dependence

 

While such goals may be a decade or more away, the roadmap is being built—one molecule, trial, and algorithm at a time.

 

A New Era of Insulin

From its first use in 1922 to its potential transformation into a smart, invisible therapy, insulin continues to evolve. What began as a groundbreaking discovery has become a dynamic platform for some of the most exciting developments in medicine.

​

Whether through a patch, a pump, a gene, or a policy change; insulin is entering a new era. And with it, the lives of millions stand to be improved, extended. Perhaps one day those millions will be freed from dependence altogether.

Resources Used for All About Insulin

American Diabetes Association. Standards of Medical Care in Diabetes—2024. Diabetes Care, American Diabetes Association, 2024. Diabetes Journals (https://diabetesjournals.org/care/issue).

​

Basu, Sanjay, et al. "Projected Need for Insulin in Type 2 Diabetes Worldwide in 2030: A Modelling Study." The Lancet Diabetes & Endocrinology, vol. 7, no. 10, 2019, pp. 698–706. The Lancet (https://www.thelancet.com/journals/landia/article/PIIS2213-8587(18)30303-6/abstract).

​

Beran, David, Margaret Ewen, and Richard Laing. "Access to Insulin: Current Challenges and Constraints." Bulletin of the World Health Organization, vol. 94, no. 4, 2016, pp. 306–308. WHO (https://www.who.int/bulletin/volumes/94/4/15-160606/en/).

​

Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report 2022. U.S. Department of Health and Human Services, 2022. CDC (https://www.cdc.gov/diabetes/php/data-research/methods.html?CDC_AAref_Val=https://www.cdc.gov/diabetes/data/statistics-report/index.html).

​

Diabetes Control and Complications Trial Research Group. "The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus." New England Journal of Medicine, vol. 329, no. 14, 1993, pp. 977–986. New England Journal of Medicine (https://www.nejm.org/doi/full/10.1056/NEJM199309303291401).

​

European Medicines Agency (EMA). Insulin Biosimilars Referral Procedure. European Medicines Agency, 2023. EMA (https://www.ema.europa.eu/en/homepage).

​

Health Action International. Insulin & Diabetes Medicine Pricing Reports. 2023. HAIWEB (https://haiweb.org/insulin-still-unattainable-many-living-diabetes-worldwide-acciss-study-review-lancet-de/).

​

International Diabetes Federation. IDF Diabetes Atlas, 10th ed., IDF, 2021. IDF (https://diabetesatlas.org/).

​

National Institutes of Health (NIH). "Insulin Gene and Protein Structure." Bookshelf – GeneReviews, National Library of Medicine, 2022. NIH (https://www.ncbi.nlm.nih.gov/books/NBK279104/).

​

PubChem. “Insulin – Compound Summary.” National Center for Biotechnology Information, 2024. PubChem (https://pubchem.ncbi.nlm.nih.gov/compound/Insulin).​

​

UK Prospective Diabetes Study (UKPDS) Group. "Intensive Blood-Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes." The Lancet, vol. 352, no. 9131, 1998, pp. 837–853. The Lancet (https://doi.org/10.1016/S0140-6736(98)07019-6).

​

Vertex Pharmaceuticals. Pipeline Overview: VX-880. Vertex, 2024. Vertex (https://www.vrtx.com/research-development/pipeline/).

​

World Health Organization. Diabetes Fact Sheet. WHO, 2023. WHO (https://www.who.int/news-room/fact-sheets/detail/diabetes).

bottom of page